“Reports of adverse events following use of the Janssen COVID-19 vaccine under emergency use authorization suggest an increased risk of immune thrombocytopenia during the 42 days following vaccination,” the FDA said in a letter to Janssen Biotech, J&J’s biotech arm.
Immune thrombocytopenia can cause easy or excessive bruising and bleeding, though the FDA said the chance of developing this disorder after vaccination is very low.
The new warning comes about a month after the CDC recommended Americans receive Pfizer or Modern’s COVID-19 vaccine over Johnson & Johnson’s due to concerns about the rare risk of blood clots following the shot.
Read the full letter here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
